$HEIA (-1,4%)
$EL (-0,99%)
$NUE (-3,24%)
$CDNS (-7,29%)
$WM (+0,32%)
$MSFT (-2,69%)
$V (+0,03%)
$OR (-0,47%)
$AZN (-0,13%)
$MRK (+0,62%)
$PG (+0,91%)
$SBUX (-1,24%)
$BCS (-3,86%)
$META (-4,12%)
$BABA (-2,95%)
$QCOM (-5,67%)
$AIR (-4,19%)
$HSBC (-3,63%)
$GSK (-0,02%)
$MBG (-1,93%)
$F (-0,22%)
$AAPL (-1,66%)
$AMZN (-3,54%)
$MA (-0,07%)
$7203 (-0,02%)
$SHEL (+0,05%)
$005930
$SNY (+1,44%)
$CMCSA (+0,53%)
$COIN (-6,43%)
$NET (-6,04%)
$XOM (+0,96%)
$CVX (+0,86%)
$CS (-0,53%)
$NTDOY (-7,52%)
$CL (+1,69%)
$DTG (-1,05%)
$UNH (+3,2%)
Sanofi ADR Representing 1 1/2
Price
Discussione su SNY
Messaggi
2Quarterly figures 28.07-01.08
Sanofi reported earnings Q4 FY2024 results ended on December 31, 2024
- Revenue: €10.56B, +10.3% YoY at CER
- Net income: €683M vs -€555M in Q4 2023
- Business EPS: €1.31, -11.0% YoY at CER
- Full year revenue: €41.1B, +11.3% YoY at CER
CEO Paul Hudson: "We achieved double-digit sales growth in 2024 while pursuing the transformation of the company. Innovation was a key driver of our growth as launches already contributed 11 percent of sales, with Beyfortus becoming a blockbuster in its first full year of sales."
🌱Revenue & Growth
- US sales: €5.15B, +13.3% YoY at CER
- Europe sales: €2.43B, +6.0% YoY at CER
- Rest of World: €2.98B, +8.8% YoY at CER
- Dupixent sales: €3.46B, +16.0% YoY at CER
- Vaccines sales: €2.18B, +10.8% YoY at CER
💰Profits & Financials
- Gross margin: 74.3%, -2.5pp YoY
- Business operating income: €2.08B, -7.7% YoY at CER
- Free cash flow: €2.34B, -25.5% YoY
- R&D expenses: €2.26B, +24.4% YoY
📌Business Highlights
- Received 14 regulatory approvals of medicines and vaccines in 2024
- Beyfortus achieved blockbuster status with €1.7B sales in first full year
- Plans to sell controlling stake in Opella consumer health business
🔮Future Outlook
- 2025 sales growth expected at mid-to-high single-digit percentage at CER
- Expects strong rebound in business EPS with low double-digit growth at CER
- Plans €5B share buyback program in 2025
- Dupixent sales expected to reach around €22B by 2030
Titoli di tendenza
I migliori creatori della settimana